Patents by Inventor Yosef Refaeli

Yosef Refaeli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20200155600
    Abstract: Provided herein are methods for adoptive cell transfer for the treatment of cancer, comprising administering a therapeutically effective amount of immune cells having antitumor activity to a subject, wherein the immune cells are contacted with a protein transduction domain (PTD)-MYC fusion polypeptide prior to administration to the subject. In some embodiments, the PTD-MYC fusion polypeptide comprises: (i) an HIV TAT protein transduction domain; and (ii) a MYC polypeptide sequence.
    Type: Application
    Filed: August 1, 2018
    Publication date: May 21, 2020
    Inventors: Yosef REFAELI, Brian C. TURNER, Gregory Alan BIRD
  • ANTIBODIES AND PROCESSES FOR PREPARING THE SAME
    Publication number: 20200148749
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Application
    Filed: October 10, 2019
    Publication date: May 14, 2020
    Inventors: Yosef REFAELI, Brian TURNER
  • Nanoparticle formulations
    Patent number: 10583156
    Abstract: This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 10, 2020
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Alan Bird
  • Compositions and methods for modulating an immune response
    Patent number: 10556006
    Abstract: Disclosed herein are methods of modulation of the viability of a cell using fusion proteins comprising a transporter peptide sequence and a MYC polypeptide. Further disclosed herein are methods of modulating an immune response using the fusion proteins. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: February 11, 2020
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • PTD-SMAD7 THERAPEUTICS
    Publication number: 20200023037
    Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 23, 2020
    Inventors: Xiao-Jing Wang, Qinghong ZHANG, Yosef REFAELI
  • PTD-SMAD7 therapeutics
    Patent number: 10456448
    Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: October 29, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Xiao-Jing Wang, Qinghong Zhang, Yosef Refaeli
  • Antibodies and processes for preparing the same
    Patent number: 10442853
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: October 15, 2019
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Turner
  • Therapeutic applications of Smad7
    Patent number: 10350265
    Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 16, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Xiao-jing Wang, Yosef Refaeli, Qinghong Zhang
  • ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT
    Publication number: 20190142870
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Application
    Filed: January 29, 2019
    Publication date: May 16, 2019
    Inventors: Brian C. TURNER, Yosef REFAELI, Gregory Alan BIRD
  • Production and use of red blood cells
    Patent number: 10272115
    Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 30, 2019
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory A. Bird
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
    Publication number: 20190060434
    Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
    Type: Application
    Filed: November 8, 2018
    Publication date: February 28, 2019
    Inventors: Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
  • Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
    Patent number: 10206952
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: February 19, 2019
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory Alan Bird
  • CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
    Publication number: 20190024051
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: July 23, 2018
    Publication date: January 24, 2019
    Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis TURNER
  • Methods and compositions for the treatment of melanoma
    Patent number: 10149898
    Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: December 11, 2018
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
  • Expansion of adult stem cells in vitro
    Patent number: 10087420
    Abstract: Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: October 2, 2018
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Bird
  • PRODUCTION AND USE OF RED BLOOD CELLS
    Publication number: 20180177827
    Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
    Type: Application
    Filed: July 6, 2017
    Publication date: June 28, 2018
    Inventors: Brian C. TURNER, Yosef REFAELI, Gregory A. BIRD
  • NANOPARTICLE FORMULATIONS
    Publication number: 20180153939
    Abstract: This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Alan Bird
  • ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT
    Publication number: 20180117089
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Application
    Filed: October 16, 2017
    Publication date: May 3, 2018
    Inventors: Brian C. TURNER, Yosef REFAELI, Gregory Alan BIRD
  • MODULATORS OF MYC, AND METHODS OF USING THE SAME
    Publication number: 20180092972
    Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 5, 2018
    Inventors: Yosef REFAELI, Brian Curtis TURNER
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
    Publication number: 20180036396
    Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
    Type: Application
    Filed: August 3, 2017
    Publication date: February 8, 2018
    Inventors: Yosef REFAELI, Brian C. TURNER, Gregory Alan Bird